A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib
Author(s) -
Thomas R. Burkard,
Uwe Rix,
Florian P. Breitwieser,
Giulio SupertiFurga,
Jacques Colinge
Publication year - 2010
Publication title -
plos computational biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.628
H-Index - 182
eISSN - 1553-7358
pISSN - 1553-734X
DOI - 10.1371/journal.pcbi.1001001
Subject(s) - imatinib , myeloid leukemia , computational biology , drug , mechanism of action , drug development , drug discovery , drug action , crosstalk , mechanism (biology) , function (biology) , bioinformatics , biology , pharmacology , cancer research , microbiology and biotechnology , biochemistry , philosophy , physics , epistemology , optics , in vitro
Prediction of drug action in human cells is a major challenge in biomedical research. Additionally, there is strong interest in finding new applications for approved drugs and identifying potential side effects. We present a computational strategy to predict mechanisms, risks and potential new domains of drug treatment on the basis of target profiles acquired through chemical proteomics. Functional protein-protein interaction networks that share one biological function are constructed and their crosstalk with the drug is scored regarding function disruption. We apply this procedure to the target profile of the second-generation BCR-ABL inhibitor bafetinib which is in development for the treatment of imatinib-resistant chronic myeloid leukemia. Beside the well known effect on apoptosis, we propose potential treatment of lung cancer and IGF1R expressing blast crisis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom